FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2541900703> ?p ?o ?g. }

• W2541900703 abstract "Rilpivirine (RPV), the latest nonnucleoside reverse transcriptase inhibitor active against HIV-1, is prescribed in a standard dosage of 25 mg once a day in combination with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF). The aim of this observational study was to characterize the RPV pharmacokinetic profile, to quantify interpatient variability, and to identify potential factors that could influence drug exposure. RPV concentration data were collected from HIV-infected patients as part of routine therapeutic drug monitoring performed in our center (Laboratory of Clinical Pharmacology). A population pharmacokinetic analysis was performed with NONMEM by comparing various structural models. The influence of demographic and clinical covariates, as well as frequent genetic polymorphisms in 5 genes (CYP3A4*22, CYP3A5*3, CYP2C19*2, CYP2C19*17, UGT1A1*28, and UGT1A4*2), on RPV elimination was explored. A total of 325 plasma concentration measurements were obtained from 249 HIV-positive patients. Plasma concentrations ranged from 12 to 255 ng/ml. A one-compartment model with zero-order absorption best characterized RPV pharmacokinetics. The average RPV clearance (CL) was 11.7 liters/h, the average volume of distribution was 401 liters, and the mean absorption time was 4 h. The interinterindividual variability (IIV) for CL was estimated to be 33%. None of the available demographic or genetic covariates showed any influence on RPV pharmacokinetics, but 29% of the patients were predicted to present minimal concentrations below the recently identified target cutoff value of 50 ng/ml. The variability in RPV pharmacokinetics appears to be lower than that for most other antiretroviral drugs. However, under the standard regimen of 25 mg daily, a significant number of patients might be underdosed. It remains to be investigated whether the underexposure has an impact on the development of resistance while patients are on maintenance therapy." @default.
• W2541900703 created "2016-11-04" @default.
• W2541900703 creator A5011217027 @default.
• W2541900703 creator A5014858344 @default.
• W2541900703 creator A5037441803 @default.
• W2541900703 creator A5046740811 @default.
• W2541900703 creator A5046807019 @default.
• W2541900703 creator A5060727310 @default.
• W2541900703 creator A5067495940 @default.
• W2541900703 creator A5082208651 @default.
• W2541900703 creator A5091531260 @default.
• W2541900703 date "2017-01-01" @default.
• W2541900703 modified "2023-10-17" @default.
• W2541900703 title "Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals" @default.
• W2541900703 cites W1486730500 @default.
• W2541900703 cites W1509307283 @default.
• W2541900703 cites W1550666015 @default.
• W2541900703 cites W1576188396 @default.
• W2541900703 cites W1915630750 @default.
• W2541900703 cites W2003143162 @default.
• W2541900703 cites W2004441521 @default.
• W2541900703 cites W2004487100 @default.
• W2541900703 cites W2004891552 @default.
• W2541900703 cites W2030358514 @default.
• W2541900703 cites W2030622120 @default.
• W2541900703 cites W2058643347 @default.
• W2541900703 cites W2058734479 @default.
• W2541900703 cites W2062900531 @default.
• W2541900703 cites W2080228333 @default.
• W2541900703 cites W2081558811 @default.
• W2541900703 cites W2089720722 @default.
• W2541900703 cites W2094404559 @default.
• W2541900703 cites W2103661657 @default.
• W2541900703 cites W2105902511 @default.
• W2541900703 cites W2122732537 @default.
• W2541900703 cites W2139149616 @default.
• W2541900703 cites W2142538462 @default.
• W2541900703 cites W2151816247 @default.
• W2541900703 cites W2169935883 @default.
• W2541900703 cites W2322601374 @default.
• W2541900703 doi "https://doi.org/10.1128/aac.00899-16" @default.
• W2541900703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5192124" @default.
• W2541900703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27799217" @default.
• W2541900703 hasPublicationYear "2017" @default.
• W2541900703 type Work @default.
• W2541900703 sameAs 2541900703 @default.
• W2541900703 citedByCount "26" @default.
• W2541900703 countsByYear W25419007032017 @default.
• W2541900703 countsByYear W25419007032018 @default.
• W2541900703 countsByYear W25419007032020 @default.
• W2541900703 countsByYear W25419007032021 @default.
• W2541900703 countsByYear W25419007032022 @default.
• W2541900703 countsByYear W25419007032023 @default.
• W2541900703 crossrefType "journal-article" @default.
• W2541900703 hasAuthorship W2541900703A5011217027 @default.
• W2541900703 hasAuthorship W2541900703A5014858344 @default.
• W2541900703 hasAuthorship W2541900703A5037441803 @default.
• W2541900703 hasAuthorship W2541900703A5046740811 @default.
• W2541900703 hasAuthorship W2541900703A5046807019 @default.
• W2541900703 hasAuthorship W2541900703A5060727310 @default.
• W2541900703 hasAuthorship W2541900703A5067495940 @default.
• W2541900703 hasAuthorship W2541900703A5082208651 @default.
• W2541900703 hasAuthorship W2541900703A5091531260 @default.
• W2541900703 hasBestOaLocation W25419007031 @default.
• W2541900703 hasConcept C112705442 @default.
• W2541900703 hasConcept C126322002 @default.
• W2541900703 hasConcept C139254425 @default.
• W2541900703 hasConcept C140840227 @default.
• W2541900703 hasConcept C142462285 @default.
• W2541900703 hasConcept C159047783 @default.
• W2541900703 hasConcept C2776239304 @default.
• W2541900703 hasConcept C2778723075 @default.
• W2541900703 hasConcept C2780272996 @default.
• W2541900703 hasConcept C2908647359 @default.
• W2541900703 hasConcept C2993143319 @default.
• W2541900703 hasConcept C3013748606 @default.
• W2541900703 hasConcept C526171541 @default.
• W2541900703 hasConcept C62231903 @default.
• W2541900703 hasConcept C71924100 @default.
• W2541900703 hasConcept C98274493 @default.
• W2541900703 hasConcept C99454951 @default.
• W2541900703 hasConceptScore W2541900703C112705442 @default.
• W2541900703 hasConceptScore W2541900703C126322002 @default.
• W2541900703 hasConceptScore W2541900703C139254425 @default.
• W2541900703 hasConceptScore W2541900703C140840227 @default.
• W2541900703 hasConceptScore W2541900703C142462285 @default.
• W2541900703 hasConceptScore W2541900703C159047783 @default.
• W2541900703 hasConceptScore W2541900703C2776239304 @default.
• W2541900703 hasConceptScore W2541900703C2778723075 @default.
• W2541900703 hasConceptScore W2541900703C2780272996 @default.
• W2541900703 hasConceptScore W2541900703C2908647359 @default.
• W2541900703 hasConceptScore W2541900703C2993143319 @default.
• W2541900703 hasConceptScore W2541900703C3013748606 @default.
• W2541900703 hasConceptScore W2541900703C526171541 @default.
• W2541900703 hasConceptScore W2541900703C62231903 @default.
• W2541900703 hasConceptScore W2541900703C71924100 @default.
• W2541900703 hasConceptScore W2541900703C98274493 @default.
• W2541900703 hasConceptScore W2541900703C99454951 @default.
• W2541900703 hasFunder F4320310212 @default.
• W2541900703 hasFunder F4320338413 @default.

• next